Copyright Reports & Markets. All rights reserved.

Global Biciruizumab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Biciruizumab Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 100 mg/4 mL
    • 1.3.3 320 mg/2 mL
  • 1.4 Market Analysis by Specification
    • 1.4.1 Overview: Global Biciruizumab Consumption Value by Specification: 2021 Versus 2025 Versus 2032
    • 1.4.2 Bimekizumab In Combination With Methotrexate
    • 1.4.3 Bimekizumab Combined With Topical Corticosteroids
  • 1.5 Market Analysis by Sales Channels
    • 1.5.1 Overview: Global Biciruizumab Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
    • 1.5.2 Hospital
    • 1.5.3 Retail
    • 1.5.4 Online
  • 1.6 Market Analysis by Dosage Form
    • 1.6.1 Overview: Global Biciruizumab Consumption Value by Dosage Form: 2021 Versus 2025 Versus 2032
    • 1.6.2 Intravenous Injection
    • 1.6.3 Subcutaneous Injection
  • 1.7 Market Analysis by Application
    • 1.7.1 Overview: Global Biciruizumab Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.7.2 Psoriasis
    • 1.7.3 Ankylosing Spondylitis
    • 1.7.4 Hidradenitis Suppurativa
    • 1.7.5 Others
  • 1.8 Global Biciruizumab Market Size & Forecast
    • 1.8.1 Global Biciruizumab Consumption Value (2021 & 2025 & 2032)
    • 1.8.2 Global Biciruizumab Sales Quantity (2021-2032)
    • 1.8.3 Global Biciruizumab Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Roche
    • 2.1.1 Roche Details
    • 2.1.2 Roche Major Business
    • 2.1.3 Roche Biciruizumab Product and Services
    • 2.1.4 Roche Biciruizumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Roche Recent Developments/Updates
  • 2.2 Chugai Pharmaceutical
    • 2.2.1 Chugai Pharmaceutical Details
    • 2.2.2 Chugai Pharmaceutical Major Business
    • 2.2.3 Chugai Pharmaceutical Biciruizumab Product and Services
    • 2.2.4 Chugai Pharmaceutical Biciruizumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Chugai Pharmaceutical Recent Developments/Updates
  • 2.3 Amgen
    • 2.3.1 Amgen Details
    • 2.3.2 Amgen Major Business
    • 2.3.3 Amgen Biciruizumab Product and Services
    • 2.3.4 Amgen Biciruizumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Amgen Recent Developments/Updates
  • 2.4 Pfizer
    • 2.4.1 Pfizer Details
    • 2.4.2 Pfizer Major Business
    • 2.4.3 Pfizer Biciruizumab Product and Services
    • 2.4.4 Pfizer Biciruizumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Pfizer Recent Developments/Updates
  • 2.5 Qilu Pharmaceutical
    • 2.5.1 Qilu Pharmaceutical Details
    • 2.5.2 Qilu Pharmaceutical Major Business
    • 2.5.3 Qilu Pharmaceutical Biciruizumab Product and Services
    • 2.5.4 Qilu Pharmaceutical Biciruizumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Qilu Pharmaceutical Recent Developments/Updates
  • 2.6 Innovent Biologics
    • 2.6.1 Innovent Biologics Details
    • 2.6.2 Innovent Biologics Major Business
    • 2.6.3 Innovent Biologics Biciruizumab Product and Services
    • 2.6.4 Innovent Biologics Biciruizumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Innovent Biologics Recent Developments/Updates
  • 2.7 Jiangsu Hengrui Medicine
    • 2.7.1 Jiangsu Hengrui Medicine Details
    • 2.7.2 Jiangsu Hengrui Medicine Major Business
    • 2.7.3 Jiangsu Hengrui Medicine Biciruizumab Product and Services
    • 2.7.4 Jiangsu Hengrui Medicine Biciruizumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Jiangsu Hengrui Medicine Recent Developments/Updates
  • 2.8 Shandong Boan Biotechnology
    • 2.8.1 Shandong Boan Biotechnology Details
    • 2.8.2 Shandong Boan Biotechnology Major Business
    • 2.8.3 Shandong Boan Biotechnology Biciruizumab Product and Services
    • 2.8.4 Shandong Boan Biotechnology Biciruizumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Shandong Boan Biotechnology Recent Developments/Updates

3 Competitive Environment: Biciruizumab by Manufacturer

  • 3.1 Global Biciruizumab Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Biciruizumab Revenue by Manufacturer (2021-2026)
  • 3.3 Global Biciruizumab Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Biciruizumab by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Biciruizumab Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Biciruizumab Manufacturer Market Share in 2025
  • 3.5 Biciruizumab Market: Overall Company Footprint Analysis
    • 3.5.1 Biciruizumab Market: Region Footprint
    • 3.5.2 Biciruizumab Market: Company Product Type Footprint
    • 3.5.3 Biciruizumab Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Biciruizumab Market Size by Region
    • 4.1.1 Global Biciruizumab Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Biciruizumab Consumption Value by Region (2021-2032)
    • 4.1.3 Global Biciruizumab Average Price by Region (2021-2032)
  • 4.2 North America Biciruizumab Consumption Value (2021-2032)
  • 4.3 Europe Biciruizumab Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Biciruizumab Consumption Value (2021-2032)
  • 4.5 South America Biciruizumab Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Biciruizumab Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Biciruizumab Sales Quantity by Type (2021-2032)
  • 5.2 Global Biciruizumab Consumption Value by Type (2021-2032)
  • 5.3 Global Biciruizumab Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Biciruizumab Sales Quantity by Application (2021-2032)
  • 6.2 Global Biciruizumab Consumption Value by Application (2021-2032)
  • 6.3 Global Biciruizumab Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Biciruizumab Sales Quantity by Type (2021-2032)
  • 7.2 North America Biciruizumab Sales Quantity by Application (2021-2032)
  • 7.3 North America Biciruizumab Market Size by Country
    • 7.3.1 North America Biciruizumab Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Biciruizumab Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Biciruizumab Sales Quantity by Type (2021-2032)
  • 8.2 Europe Biciruizumab Sales Quantity by Application (2021-2032)
  • 8.3 Europe Biciruizumab Market Size by Country
    • 8.3.1 Europe Biciruizumab Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Biciruizumab Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Biciruizumab Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Biciruizumab Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Biciruizumab Market Size by Region
    • 9.3.1 Asia-Pacific Biciruizumab Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Biciruizumab Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Biciruizumab Sales Quantity by Type (2021-2032)
  • 10.2 South America Biciruizumab Sales Quantity by Application (2021-2032)
  • 10.3 South America Biciruizumab Market Size by Country
    • 10.3.1 South America Biciruizumab Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Biciruizumab Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Biciruizumab Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Biciruizumab Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Biciruizumab Market Size by Country
    • 11.3.1 Middle East & Africa Biciruizumab Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Biciruizumab Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Biciruizumab Market Drivers
  • 12.2 Biciruizumab Market Restraints
  • 12.3 Biciruizumab Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Biciruizumab and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Biciruizumab
  • 13.3 Biciruizumab Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Biciruizumab Typical Distributors
  • 14.3 Biciruizumab Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Biciruizumab market size was valued at US$ 2592 million in 2025 and is forecast to a readjusted size of US$ 8879 million by 2032 with a CAGR of 14.6% during review period.
    Bevacizumab is a recombinant humanized monoclonal antibody primarily used for the treatment of various types of cancer, including colorectal cancer, non-small cell lung cancer, and renal cell carcinoma. It works by targeting and inhibiting the action of vascular endothelial growth factor (VEGF), preventing the formation of new blood vessels in tumors, thus reducing tumor blood supply and inhibiting tumor growth and spread. Bevacizumab is widely used in combination cancer therapies, typically in conjunction with chemotherapy or other targeted drugs to enhance therapeutic efficacy. The drug is administered intravenously and has been approved for clinical use in multiple countries and regions.In 2025, global Bimekizumab production reached approximately 1.2 million vials.
    Bevacizumab holds an important position in the global cancer drug market, especially in the treatment of various solid tumors, such as colorectal cancer, non-small cell lung cancer, and renal cell carcinoma. With the continuous rise in cancer prevalence and ongoing innovations in cancer treatment, the market demand for Bevacizumab is steadily increasing. This drug works by inhibiting vascular endothelial growth factor (VEGF), blocking tumor angiogenesis, and significantly improving treatment outcomes, particularly when used in combination with chemotherapy and other targeted therapies. The market prospects for Bevacizumab are very promising, particularly in developing countries and emerging markets, where improvements in healthcare infrastructure and the widespread adoption of cancer screening will benefit more patients. Although Bevacizumab is priced relatively high and faces competition from generic drugs, it remains a core component of many cancer treatment regimens. Additionally, as research into Bevacizumab’s use in other cancer types continues to expand, it is expected that the drug’s indications will continue to grow, further driving market growth.
    This report is a detailed and comprehensive analysis for global Biciruizumab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Biciruizumab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Biciruizumab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Biciruizumab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Biciruizumab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Biciruizumab
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Biciruizumab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Chugai Pharmaceutical, Amgen, Pfizer, Qilu Pharmaceutical, Innovent Biologics, Jiangsu Hengrui Medicine, Shandong Boan Biotechnology, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Biciruizumab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    100 mg/4 mL
    320 mg/2 mL
    Market segment by Specification
    Bimekizumab In Combination With Methotrexate
    Bimekizumab Combined With Topical Corticosteroids
    Market segment by Sales Channels
    Hospital
    Retail
    Online
    Market segment by Dosage Form
    Intravenous Injection
    Subcutaneous Injection
    Market segment by Application
    Psoriasis
    Ankylosing Spondylitis
    Hidradenitis Suppurativa
    Others
    Major players covered
    Roche
    Chugai Pharmaceutical
    Amgen
    Pfizer
    Qilu Pharmaceutical
    Innovent Biologics
    Jiangsu Hengrui Medicine
    Shandong Boan Biotechnology
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Biciruizumab product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Biciruizumab, with price, sales quantity, revenue, and global market share of Biciruizumab from 2021 to 2026.
    Chapter 3, the Biciruizumab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Biciruizumab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Biciruizumab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Biciruizumab.
    Chapter 14 and 15, to describe Biciruizumab sales channel, distributors, customers, research findings and conclusion.

    Buy now